On Nov 9, 2020, RemeGen Limited (9995.HK) was successfully listed on the Main Board of the Hong Kong Stock Exchange. With pre-IPO valuation of nearly US$1.4 billion, RemeGen raised HK$3.99 billion, making it the largest IPO of Chapter 18A biotech companies (not including dual listing).
Against the background of the US general election uncertainty and the unstable environment of global market, the capital market still demonstrated sufficient confidence in RemeGen with high-quality cornerstone investors participating in the public offering.
Huatai Financial acted as the Joint Sponsor, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager for the deal. RemeGen issued approximately 76.5 million shares worldwide at an issue price of HK$52.1 per share, raising a total amount of HK$4.58 billion (after the exercise of the over-allotment option).
Founded in 2008, RemeGen is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally. Among drug candidates of RemeGen as of 21 Dec, 2020, six are in clinical development stage (the NDA for telitacicept in China for systemic lupuseryth ematosus and disitamab vedotin in China for gastric cancer was accepted by NMPA) and more than five have filed the investigational new drug (IND) application or are in IND filing preparation stage.